362 related articles for article (PubMed ID: 12620735)
41. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008.
Danaei G; Singh GM; Paciorek CJ; Lin JK; Cowan MJ; Finucane MM; Farzadfar F; Stevens GA; Riley LM; Lu Y; Rao M; Ezzati M;
Circulation; 2013 Apr; 127(14):1493-502, 1502e1-8. PubMed ID: 23481623
[TBL] [Abstract][Full Text] [Related]
42. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.
Stevens W; Peneva D; Li JZ; Liu LZ; Liu G; Gao R; Lakdawalla DN
BMC Health Serv Res; 2016 May; 16():175. PubMed ID: 27165638
[TBL] [Abstract][Full Text] [Related]
43. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis.
Basu S; Wagner RG; Sewpaul R; Reddy P; Davies J
Lancet Glob Health; 2019 Feb; 7(2):e270-e280. PubMed ID: 30528531
[TBL] [Abstract][Full Text] [Related]
44. Potential effect of salt reduction in processed foods on health.
Hendriksen MA; Hoogenveen RT; Hoekstra J; Geleijnse JM; Boshuizen HC; van Raaij JM
Am J Clin Nutr; 2014 Mar; 99(3):446-53. PubMed ID: 24335058
[TBL] [Abstract][Full Text] [Related]
45. Explaining significant differences in subjective and objective measures of cardiovascular health: evidence for the socioeconomic gradient in a population-based study.
Mosca I; Bhuachalla BN; Kenny RA
BMC Cardiovasc Disord; 2013 Aug; 13():64. PubMed ID: 24119371
[TBL] [Abstract][Full Text] [Related]
46. Lifetime health and economic benefits of weight loss among obese persons.
Oster G; Thompson D; Edelsberg J; Bird AP; Colditz GA
Am J Public Health; 1999 Oct; 89(10):1536-42. PubMed ID: 10511836
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness analysis of population-based tobacco control strategies in the prevention of cardiovascular diseases in Tanzania.
Ngalesoni F; Ruhago G; Mayige M; Oliveira TC; Robberstad B; Norheim OF; Higashi H
PLoS One; 2017; 12(8):e0182113. PubMed ID: 28767722
[TBL] [Abstract][Full Text] [Related]
48. Scaling hypertension treatment in 24 low-income and middle-income countries: economic evaluation of treatment decisions at three blood pressure cut-points.
Hutchinson B; Walter A; Campbell N; Whelton PK; Varghese C; Husain MJ; Nugent R; Kostova D; Honeycutt A
BMJ Open; 2024 Apr; 14(4):e071036. PubMed ID: 38626959
[TBL] [Abstract][Full Text] [Related]
49. Cost and consequence analysis of the Healthy Choices at Work programme to prevent non-communicable diseases in a commercial power plant, South Africa.
Schouw DD; Mash R
Afr J Prim Health Care Fam Med; 2020 Jun; 12(1):e1-e8. PubMed ID: 32634016
[TBL] [Abstract][Full Text] [Related]
50. Economic Benefit-Cost Analysis of Select Secondary Prevention Interventions in LMIC.
Nugent R; Brouwer E
Glob Heart; 2015 Dec; 10(4):319-21. PubMed ID: 26704964
[TBL] [Abstract][Full Text] [Related]
51. Quantifying the economic benefits of prevention in a healthcare setting with severe financial constraints: the case of hypertension control.
Athanasakis K; Kyriopoulos II; Boubouchairopoulou N; Stergiou GS; Kyriopoulos J
Clin Exp Hypertens; 2015; 37(5):375-80. PubMed ID: 25496288
[TBL] [Abstract][Full Text] [Related]
52. Projecting burden of hypertension and its management in Turkey, 2015-2030.
Yurekli AA; Bilir N; Husain MJ
PLoS One; 2019; 14(9):e0221556. PubMed ID: 31509548
[TBL] [Abstract][Full Text] [Related]
53. [The cost-utility ratio of reducing salt intake and its impact on the incidence of cardiovascular disease in Argentina].
Ferrante D; Konfino J; Mejía R; Coxson P; Moran A; Goldman L; Pérez-Stable EJ
Rev Panam Salud Publica; 2012 Oct; 32(4):274-80. PubMed ID: 23299288
[TBL] [Abstract][Full Text] [Related]
54. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden.
Lawes CM; Vander Hoorn S; Law MR; Elliott P; MacMahon S; Rodgers A
J Hypertens; 2006 Mar; 24(3):423-30. PubMed ID: 16467640
[TBL] [Abstract][Full Text] [Related]
55. Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?
Grover SA; Coupal L; Kaouache M; Lowensteyn I
Can J Cardiol; 2007 May; 23(6):467-73. PubMed ID: 17487292
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of risk stratified medication management for reducing premature cardiovascular mortality in Kenya.
Subramanian S; Hilscher R; Gakunga R; Munoz B; Ogola E
PLoS One; 2019; 14(6):e0218256. PubMed ID: 31237910
[TBL] [Abstract][Full Text] [Related]
57. The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight).
Roseleur J; Gonzalez-Chica DA; Harvey G; Stocks NP; Karnon J
Pharmacoeconomics; 2023 May; 41(5):573-587. PubMed ID: 36870035
[TBL] [Abstract][Full Text] [Related]
58. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina.
Rubinstein A; García Martí S; Souto A; Ferrante D; Augustovski F
Cost Eff Resour Alloc; 2009 May; 7():10. PubMed ID: 19419570
[TBL] [Abstract][Full Text] [Related]
59. Willingness-to-pay for a population program aimed at reducing dietary salt in Denmark.
Kristiansen IS; Gyrd-Hansen D; Nexøe J; Bo Nielsen J
Prev Med; 2006 Jul; 43(1):31-5. PubMed ID: 16678893
[TBL] [Abstract][Full Text] [Related]
60. Pharmacoeconomic evaluation of risk factors for cardiovascular disease: an epidemiological perspective.
Fletcher AE; Bulpitt CJ
Pharmacoeconomics; 1992 Jan; 1(1):33-44. PubMed ID: 10147038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
